Anterogen.Co.,Ltd. (KOSDAQ: 065660)

Market Cap	136.53B
Revenue (ttm)	6.66B
Net Income (ttm)	-2.31B
Shares Out	9.73M
EPS (ttm)	-237.90
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	5,980
Open	14,030
Previous Close	14,250
Day's Range	13,920 - 14,560
52-Week Range	12,300 - 19,150
Beta	n/a
Analysts	n/a
Price Target	n/a
Earnings Date	n/a

About Anterogen.Co.,Ltd.

Anterogen.Co.,Ltd., a bio-venture company, engages in the research, development, and commercialization of cell therapy products using adipose-derived stem cells in South Korea and internationally. The company offers medicines, including Cupistem injection, an adipose stem cell product that is used for the treatment of Crohn’s fistula; Queencell, a stromal vascular fraction used for the regeneration of subcutaneous adipose tissue; and Remodulin injection, a medicine for the treatment of pulmonary arterial hypertension. It also provides cosmetics...

• Industry: Biological Products, Except Diagnostic Substances
• Founded: 2000
• Country: South Korea
• Stock Exchange: KOSDAQ
• Ticker Symbol: 065660

Financial Performance

In 2023, Anterogen.Co.,Ltd.'s revenue was 6.50 billion, a decrease of -1.38% compared to the previous year's 6.59 billion. Losses were -2.84 billion, -58.45% less than in 2022.